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Cytotoxins directed to interleukin-4 receptors have shown to mediate relatively selective cytotoxicity against a variety of
human cancer cells in vitro and in vivo. In an ongoing Phase I clinical trial, a recombinant protein comprised of circularly
permuted IL-4 fused to a mutated form of Pseudomonas exotoxin (the fusion protein termed IL-4(38-37)-PE38KDEL or cpIL4-
PE) has shown antitumour activity against malignant glioma. Human medulloblastomas are neuroectodermal tumours that
occur in children and have a poor prognosis. The goal of this study was to determine whether human medulloblastoma
derived cell lines express interleukin-4 receptor and whether interleukin-4 receptor expression is accompanied by sensitivity to
cpIL4-PE. Medulloblastoma cell lines express interleukin-4 receptor at the protein and mRNA levels as determined by binding,
indirect immunoﬂuorescence and RT–PCR studies. These cells expressed IL-4Ra (also known as IL-4Rb) and IL-13Ra1 (also
known as IL-13Ra') chains, however common gc, a component of the interleukin-4 receptor system in immune cells was not
detected. Consistent with the expression of IL-4R, cpIL4-PE was found to be highly and speciﬁcally cytotoxic to four of ﬁve
medulloblastoma cell lines. Susceptibility of medulloblastoma cell lines to cpIL4-PE seemed to correlate closely to the
functional IL-4 binding sites in general as demonstrated by
125I-IL-4 binding, but did not seem to correlate with mRNA or cell
surface immunoreactive receptor protein expression. The sensitivity of medulloblastoma cells to cpIL4-PE could be eliminated
by concurrent incubation with IL-4 or IL-13, but not with IL-2. None of these cell lines showed any change in proliferation
upon treatment with exogenous IL-4. These studies establish the interleukin-4 receptor as a medulloblastoma-associated
target for possible tumour-directed cancer therapy. Further studies are warranted to investigate interleukin-4 receptor
expression in primary medulloblastoma tumours and sensitivity to cpIL-4PE in vitro and in vivo.
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Medulloblastomas are malignant brain tumours of neuroectoder-
mal origin that arise in the cerebellum. They primarily occur in
children within the ﬁrst decade of life and carry a poor prognosis
in the advanced stage of the disease (Stevens et al, 1991). New
active agents are needed to improve survival and enhance the qual-
ity of life of these patients. Our previous studies have identiﬁed
abundant expression of receptors for IL-4 (IL-4R) on human brain
tumour cells (Husain et al, 1998; Joshi et al, 2000; Puri et al, 1994,
1996a). Based on our preclinical efﬁcacy and safety studies, we have
begun a Phase I clinical trial, in which a recombinant chimeric
protein composed of circularly permuted IL-4 fused with Pseudo-
monas exotoxin (cpIL4-PE or IL4(38-37)-PE38KDEL) is
administered intratumouraly in patients with high-grade glioma
(Rand et al, 2000). Preliminary results suggest that cpIL4-PE given
by this route is safe and has antitumour activity in some recurrent
gliomas. Thus, medulloblastoma patients may beneﬁt from targeted
cancer therapeutics, which have low toxicity and high speciﬁcity.
In addition to demonstrating expression of IL-4R on cancer cells
includingbraintumourcells,wehaveextensivelystudiedthestructure
andsignaltransductionofIL-4Roncancercells(Kawakamietal,2000;
Leland et al, 2000; Murata et al, 1995, 1997a,b, 1998a,b; Obiri et al,
1993, 1997). We have shown that the IL-4R exists in three different
types (Murata et al, 1995, 1998a). Type I (classical) IL-4Rs are
composed of IL-4Ra (also known as IL-4Rb) and IL-2Rg chain (gc),
while type II (alternative) receptors are composed of IL-4Ra and IL-
13Ra1 subunits (Kawakami et al, 2000; Leland et al, 2000; Murata et
al,1995, 1997a,b).In somecell typesall threechains arepresent (Type
III IL-4R). From reconstitution studies, we have observed that IL-4
forms a complex with only two chains of IL-4R at a time even when
all three chains were transfected in CHO-K1 cells (Murata et al,
1998b). Whether all three chains form a productive IL-4R complex is
still not known. We and others have shown that type I IL-4R are
expressed in immune cells e.g., T and B lymphocytes, monocytes,
and haematological malignancies (Puri, 1995). Type II IL-4R is
expressedinthemajorityofsolidtumourcellsexaminede.g.,glioblas-
toma, breast carcinoma, AIDS-associated Kaposi’s tumour, head and
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sneck cancer, renal cell carcinoma and others (Murata et al, 1998a).
Type III IL-4R is expressed predominantly in B cells and monocytes.
Besides the dissimilarity in structure between haematological
and non-haematological cells, the signalling by IL-4R in these cells
is also different. In immune cells, IL-4 primarily signals through
Jak1 and Jak3 tyrosine kinases while in non-immune cells IL-4
signals through Jak1 and Jak2 tyrosine kinases (Murata et al,
1995, 1998a). Even though proximal signal transduction by differ-
ent types of IL-4R is different, the distal signalling through signal
transduction and activator of transcription (STAT) is the same.
All types of IL-4R phosphorylate and activate STAT-6 protein
(Murata et al, 1995, 1998a,b).
The signiﬁcance of expression of IL-4R on solid tumour cells is
not known. It is also not known whether human medulloblastoma
cells express IL-4R and, if they do, which chains of these receptors
are present on medulloblastoma tumour cells. In the present study,
we have examined the mRNA and protein expression of various
receptor subunits of IL-4R by RT–PCR, radiolabelled binding,
and indirect immunoﬂuorescence assays in different medulloblasto-
ma cell lines. In addition, we have tested the cyototoxic effect of
cpIL4-PE on various medulloblastoma cell lines.
MATERIALS AND METHODS
Medulloblastoma cell lines
UW-228-1, UW-228-2 and UW-228-3 cell lines were derived from
a medulloblastoma tumour and generated at Washington Univer-
sity, Seattle, WA, USA (Keles et al, 1995). D283, and D341 cell
lines were purchased from the American Type Culture Collection
(ATCC), Manassas, VA, USA. All these cell lines grew as mono-
layers except D283, which grew mostly in suspension while D341
cell line grew as a suspension cell line. PM-RCC, renal cell carcino-
ma cell line was derived in our laboratory (Obiri et al, 1993) and
H-9 T cells were purchased from ATCC. These cell lines were
cultured in DMEM medium containing 10% foetal bovine serum
(Biowhittaker, Walkersville, MD, USA), 1 mM HEPES, 1 mM
non-essential amino acids, 100 units ml
71 penicillin, and
100 mgm l
71 streptomycin (Biowhittaker).
Recombinant cytokines and toxins Recombinant circularly
permuted IL4-toxin IL4(38-37)-PE38KDEL was produced and puri-
ﬁed to 495% homogeneity as described previously (Kreitman et al,
1994, 1995b; Puri et al, 1996b). Recombinant IL-4 and IL-13 were
produced as described (Kreitman et al, 1995a; Oshima et al, 2000).
RNA extraction
Total RNA was extracted from medulloblastoma cell lines using the
Trizol reagent (Gibco, Gaithersburg, MD, USA) as per manufac-
turer’s instructions. Brieﬂy, 5610
6 cells were pelleted and lysed
with the reagent and centrifuged after adding chloroform. The
RNA from aqueous phase was separated and precipitated with cold
isopropanol. The pellet was washed with 70% ethanol twice, dried
and reconstituted with RNase free water. RNA was quantitated
after measuring the optical densities at 260 and 280 nm in a spec-
trophotometer and stored at 7708C.
Reverse Transcriptase-Polymerase Chain Reaction
(RT–PCR)
Levels of IL-4R subunit mRNA were determined by RT–PCR using
primers and conditions previously described (Murata et al, 1997a).
Immunoﬂuorescence assay
Twenty thousand cells from different medulloblastoma cell lines
were cultured in chambered glass slides (Lab Tek- Nalge Nunc
International, Naperville, IL, USA) for 48 h as described (Joshi
et al, 2000). The cells were washed with PBS and ﬁxed in cold
methanol:acetone (1:1) and incubated at 7208C for 2 h. The
slides were then washed and rehydrated with PBS and used for
indirect immunoﬂuorescence analysis. Monoclonal antibody
against IL-13Ra1 was purchased from Diaclone, Besancon,
France. Mouse monoclonal antibody (M57) against IL-4Ra chain
was a kind gift from Immunex Corporation, Seattle, WA, USA
and polyclonal rabbit anti gc antibody was purchased from Santa
Cruz, California, USA. Rehydrated cells in the chambered slide
were incubated with 1% bovine serum albumin, 5% either goat
or horse serum in PBS to block non-speciﬁc binding of anti-
body. The slides were washed and incubated either with the
speciﬁed primary antibody (1:1500 for mAb IL-13Ra1, rabbit
polyclonal and mAb for IL-4Ra) or isotype control (mouse
IgG1 for IL-13Ra1 and IL-4Ra or rabbit IgG) for 2 h at room
temperature. Slides were then washed three times with PBS for
5 min at room temperature and stained with secondary antibo-
dies conjugated to either TRICT or FITC which were diluted
in PBS containing 0.1% BSA as per manufacturer’s recommenda-
tion. After three washes with PBS, slides were dried and layered
with Vectashield anti-ﬂuorescence fading mounting medium
Table 1 Expression of IL-4 receptor and cytotoxicity of cpIL4-PE on
human medulloblastoma cell lines
IL-4 binding IC50
Tumour cells sites/cell
a (ng ml
71)
b
UW-228-1 1050+18 1
UW-228-2 1007+22 1.4+0.5
UW-228-3 952+44 0.9+0.2
D283 145+46 41000
D341 592+52 30
aSingle saturating concentration of
125I-IL-4 was used to calculate binding sites. Results
are shown as mean+s.d. from one of two representative experiments. The results
for UW-228-1 and D341 cell lines are mean+s.d. of single experiment performed
in duplicate.
bIC50, the concentration of cpIL4-PE at which 50% inhibition of protein
synthesis is observed compared to untreated cells. The results are shown as mean+
s.e.m. of two independent experiments.
Table 2 mRNA expression of various chains of IL-4R complex by
RT–PCR analysis in human medulloblastoma cell lines
Cell line IL-4Ra IL-13Ra1
UW228-1 +++ ++
UW228-2 +++ ++
UW228-3 +++ ++
D283 +++ +
D341 +++ ++
+, mild expression; ++, moderate expression; +++, strong expression.
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Figure 1 mRNA transcripts for IL-4R subunits. RT–PCR products were
resolved in 2% agarose gel and visualized by EtBR staining. PM-RCC RNA
served as positive control for IL-IL-13Ra1 and IL-4Ra chains.
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s(Vector Laboratories, Burlingame, CA, USA) and cover slipped.
The slides were viewed in a Nikon epiﬂuorescence microscope
using appropriate ﬁlters.
125I-IL-4 binding and displacement assay
IL-4 was iodinated with IODOGEN reagent (Pierce, Rockford, IL,
USA) according to manufacturer’s instructions. The speciﬁc activ-
ity of radiolabelled IL-4 was *22 mCi mg
71. The IL-4 binding
assay was performed as previously described (Obiri et al, 1993; Puri
et al, 1991). Brieﬂy, tumour cells were harvested after brief incuba-
tion with versene (Biowhittaker, Walkersville, DE, USA), washed
three times in Hanks balanced salt solution and resuspended in
binding buffer (RPMI 1640 plus 1 mM HEPES and 0.2% human
serum albumin). For the displacement assay, medulloblastoma cells
(1610
6/100 ml) were incubated at 48C with
125I-IL-4 (100–
200 pM) with or without 200-fold molar excess of unlabelled IL-
4. Following a 2 h incubation, cell bound radio-ligand was sepa-
rated from unbound by centrifugation through a phthalate oil
gradient and radioactivity determined with a gamma counter
(Wallac). The number of receptors and binding afﬁnities were
determined as previously described (Obiri et al, 1993; Puri et al,
1991).
Protein synthesis inhibition assays The cytotoxic activity of
IL4-toxins was determined by protein synthesis inhibition assay
as previously described (Puri et al, 1991). Protein synthesis inhibi-
tion directly correlates with cell death (Puri et al, 1996b). Typically,
10
4 medulloblastoma cells were cultured in leucine-free medium
with or without various concentrations of cpIL4-PE for 20–22 h
UW228-2 UW228-3
D 283
A B
C
Figure 2 Immunoﬂuorescence analysis of various receptor chains on medulloblastoma cell lines. (A) UW228-2, (B) UW228-3, and (C) D283 medullo-
blastoma cell lines were stained with either murine IgG1 isotype control or mouse monoclonal antibody to IL-4Ra chain or IL-13Ra1 chains. D283 cell line
grew as a suspension culture showing few cells positive in the microscopic ﬁeld.
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sat 378C. For competition studies, cells were pre-incubated with IL-
4 or IL-13 or IL-2 (2 mgm l
71) for 30 min at 378C prior to the
addition of cpIL4-PE to the cells. Then 1 mCi of
3H-Leucine
(NEN Research Products, Wilmington, DE, USA) was added to
each well and cells were incubated for an additional 4 h. Cells were
harvested and radioactivity incorporated into cells was measured by
a Beta plate counter (Wallac, Gaithersburg, MD, USA).
Cell proliferation assay Proliferation assays were performed as
described previously (Leland et al, 1995). Brieﬂy, the cells were
washed, and resuspended in CM in which the FBS content was
reduced to 2%. 2610
4 cells for each cell line were plated in a
96-well plate and cultured for 6 h at 378C in a 5% CO2 incubator.
IL-4 (0.1–1000 ng ml
71) was added to the cultures and incubated
further for 16 h. The cells were then pulsed with [
3H]-thymidine
(1 mCi well
71) for an additional 8 h and frozen at 7708C. The
plates were thawed, harvested and radiolabel uptake was measured
by a Beta plate counter (Wallac, Gaithersburg, MD, USA).
RESULTS
Expression of IL-4 binding sites and IL-4 receptor chains
in medulloblastoma cell lines
By radiolabelled IL-4 binding assays, all ﬁve medulloblastoma cell
lines tested were found to express varying numbers of IL-4 recep-
tors (Table 1). Subsequent RT–PCR analysis revealed that all ﬁve
medulloblastoma cell lines expressed similar levels of mRNA for IL-
4Ra and IL-13Ra1 chains, except D283 cell line which appear to
show moderate expression for IL-13Ra1 chain as the intensity of
mRNA band was lower compared to other cell lines (Table 2,
Figure 1). For a positive control, PM-RCC cells expressed mRNA
for IL-4Ra and IL-13Ra1 chains. PM-RCC have been previously
shown to express IL-4Ra and IL-13Ra1 chains (Obiri et al, 1997).
We next examined the expression of various IL-4R receptor
chains by indirect immunoﬂuorescence assays in ﬁve different
medulloblastoma cells lines. As shown in Figure 2, immunoﬂuores-
cence staining for IL-4Ra and IL-13Ra1 chains was very intense in
UW228-2, UW228-3 and D283 cell lines. In contrast, the immuno-
ﬂuorescence staining of cells with matched isotype control antibody
did not reveal any staining at all. Interestingly, D283 cell line
showed strong immunoreactivity with a small number of cells even
though the microscopic ﬁeld shown had more cells. These results
indicate that IL-4R expression is heterogeneous and all cells do
not express IL-4R. Similar IL-4R staining results were observed
in UW228-1 and D341 cell lines (data not shown). In contrast,
IL-2Rgc protein was not detected in all ﬁve medulloblastoma cell
lines tested (data not shown).
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Figure 3 Cytotoxicity of cpIL-4-PE against medullobalstoma cell lines.
Ten thousand cells were cultured with various concentrations of cpIL4-
PE. Cells were then pulsed with 1 mCi [
3H]-Leucine and cell-associated
radioactivity was measured with a Beta Plate Counter. The results are
shown as mean +s.d. of quadruplicate determinations and the experiment
was repeated two times.
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Figure 4 Both IL-4 and IL-13, but not IL-2 neutralize the cytotoxic activ-
ity of cpIL4-PE: (A) UW-228-2 and (B) UW228-3 cells (10
4) were cul-
tured with various concentrations of cpIL4-PE. For blocking experiments,
cells were pre-incubated with IL-2, IL-4 or IL-13 (2 mgm l
71) for 30 min
prior to the addition of cpIL4-PE. Data are shown as mean +s.d. of quad-
ruplicate determination.
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sMedulloblastoma cell lines are highly sensitive to the
cytotoxic effect of cpIL4-PE
To determine whether IL-4R on medulloblastoma cell lines could
be used as a therapeutic target, we tested sensitivity of these cells
to cpIL4-PE. CpIL4-PE is a chimeric protein in which amino acids
38–129 of IL-4 were fused via a peptide linker to amino acids 1–
37, which are in turn fused to amino acids 353–364 and 381–608
of PE, with KDEL at positions 609–612 (Kreitman et al, 1994,
1995b; Puri et al, 1996b). This puriﬁed fusion protein was found
to be highly and speciﬁcally cytotoxic to a variety of human solid
tumour cell lines including glioblastoma multiforme (GBM) in
vitro (Puri et al, 1996a,b). We have also shown that this cytotoxin
is highly active in the regression of established human xenografts in
nude mice. Thus far, cpIL4-PE has been tested against epidermoid,
GBM, AIDS-KS, and breast tumour models (Husain et al, 1998,
1999; Kreitman et al, 1995b; Leland et al, 2000). Remarkable anti-
tumour activity including complete disappearance of established
disease has been observed. As in vitro sensitivity to cpIL4-PE seems
to correlate with IL-4R expression and in vivo antitumour activity
and medulloblastoma cells expressed IL-4R, we tested whether
cpIL4-PE is also cytotoxic to medulloblastoma cell lines.
As shown in Figure 3 and Table 1, three of ﬁve medulloblastoma
cell lines expressing 4900 IL-4 binding sites/cell were highly sensi-
tive to the cytotoxic activity of cpIL4-PE (IC50=1 ng ml
71). While
one cell line (D341), which expressed *600 sites/cell was moder-
ately sensitive (IC50=30 ng ml
71) and one cell line (D283),
which expressed the lowest level of IL-4R, was not sensitive to
cpIL4-PE at concentrations up to 1000 ng ml
71. Thus, cpIL4-PE
induced cytotoxicity positively correlated with IL-4 binding sites/
cell. The cytotoxic activity of cpIL4-PE was neutralized by addition
of excess IL-4 and also by IL-13 in UW-228-2 and UW-228-3 cell
lines. As excess of IL-2 did not neutralize the cytotoxicity of cpIL4-
PE, these results indicate IL-4R are related to IL-13R on medullo-
blastoma cell lines and cytotoxicity mediated by cpIL-4PE is
somewhat speciﬁc (Figure 4). This property of sharing of receptors
for IL-4 and IL-13 has also been observed in other cancer cell lines
and thus appears to be universal (Kawakami et al, 2000; Leland et
al, 2000; Murata et al, 1997b).
IL-4 does not modulate growth of medulloblastoma cell
lines
Since IL-4 has been shown to modulate growth of various tumour
cell lines (Puri, 1995), we examined whether it modulated growth
of human medulloblastoma cell lines. As shown in Figure 5, IL-4
did not alter [
3H]-thymidine incorporation in any cell line tested
even with IL-4 up to a concentration of 1000 ng ml
71. These
results indicate that IL-4 does not modulate growth of medullo-
blastoma cell lines.
DISCUSSION
We demonstrate that medulloblastoma cell lines express IL-4R that
serve as a sensitive target for IL-4R-targeted agent, cpIL4-PE.
Medulloblastoma cell lines were found to over-express IL-4Ra
and IL-13Ra1 chains. We have previously shown that a large
number (41 of 46 samples) of glioblastoma biopsy samples or
primary cell cultures are positive for IL-4Ra and IL-13Ra1 chains
as determined by RT–PCR and immunoﬂuorescence analyses
(Joshi et al, 2000; Puri et al, 1996a). Our present results conﬁrm
those observations and demonstrate that medulloblastoma cell lines
also express IL-4Ra and IL-13Ra1 chains in all cell lines tested. The
absence of gc protein indicated that medulloblastoma cell lines
express type II IL-4R as do malignant glioma cells. This conﬁgura-
tion is similar to that observed on other tumour cells including
renal cell carcinoma, AIDS-Kaposi’s tumours, head and neck
tumours, colon carcinoma, ovarian carcinoma and breast tumour
cells (Husain et al, 1997; Kawakami et al, 2000; Kreitman et al,
1994; Leland et al, 2000; Murata et al, 1997b; Puri et al, 1996b).
It is intriguing to note that D283 cell line expressed both chains
of IL-4R (IL-4Ra and IL-13Ra1) at the mRNA and protein levels
by RT–PCR and indirect immunoﬂuorescence studies, respec-
tively. However, upon direct binding study, it only expressed
about 145 IL-4 binding sites/cell. Consistent with low IL-4 binding,
this cell line was not sensitive to the cytotoxic activity of cpIL4-PE.
The direct binding studies, using
125I-IL-4 did not correlate with
either immunoﬂuorescent detection of cell surface IL-4/IL-13
receptor subunits or their mRNA transcripts. Thus, these assays
may not be able to predict as to which tumours are likely to
respond to cytotoxin-based therapy. Therefore, other assays may
be required. It is possible that D283 cell line expresses a mutated
form of IL-4R, which does not allow binding of IL-4. However, this
mutation does not affect its detection by RT–PCR and indirect
immunoﬂuorescence assays.
In a recent study, we have observed that one normal brain tissue
and single available normal human astrocytic (NHA) primary cell
culture expressed mRNA for IL-4Ra and IL-13Ra1 chains (Joshi
et al, 2000). Upon indirect immunoﬂorescence studies the NHA
primary cell culture was shown to express these chains at the cell
surface. In another study, Liu et al (2000) have also demonstrated
that IL-4R are expressed in normal human astrocytes and glioma
cells conﬁrming our initial observations. Thus, it appears that
NHA also express type II IL-4R. Additional samples including
paediatric brain are being examined to conﬁrm or dispute these
observations.
Although expression of IL-4Ra and IL-13Ra1 chains may form a
functional IL-4R complex, it is not known whether this receptor
complex will internalize the cpIL4-PE after binding. It is also not
known whether cpIL4-PE is cytotoxic to normal brain tissues. In
our Phase I clinical trial, we did not see any microscopic damage
to normal brain tissues in three patients (in which intraoperative
biopsy was obtained) that received 0.2, 2 and 6 mgm l
71 doses of
cpIL4-PE, respectively. In addition, in our recent study, we have
found that cpIL4-PE is not cytotoxic or modestly cytotoxic to a
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Figure 5 Exogenous IL-4 does not modify the growth of medulloblasto-
ma cells: 2610
4 cells of ﬁve medulloblastoma cell lines were grown in the
absence or presence of 0.1 ng to 1000 ng ml
71 IL-4. The cells were pulsed
with 1 mCi of [
3H]-thymidine and harvested after 8 h. The incorporated
radiolabelled thymidine was measured and shown as per cent of control.
Data are shown as mean +s.d. of quadruplicate determinations.
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sneuronal cell line and NHA cell culture compared to 15 glioma
primary cell cultures in which cpIL-4PE is highly cytotoxic (Joshi
et al, unpublished results). Furthermore, it is known that resting
B cells, monocytes, bone marrow cells and endothelial cells which
express type I or type II IL-4 receptors are not sensitive to cpIL4-
PE (Husain et al, 1997; Puri et al, 1994). These results suggest that
there is a large therapeutic window in which one can target cpIL4-
PE to cancer cells but cause little collateral damage to normal brain
tissues or other immune and non-immune cells. Additional
primary normal brain tissues particularly normal cerebellum tissue
samples need to be tested for sensitivity to cpIL4-PE.
We have previously observed that none of the solid tumour cell
lines including glioma cell lines secrete IL-4. Therefore, IL-4 does
not appear to be an autocrine growth factor for tumour cell lines.
However, exogenous IL-4 has been shown to mediate contrasting
effects on various tumour cell lines. For example, IL-4 can mediate
modest inhibition of proliferation of human renal cell carcinoma
(Obiri et al, 1993), melanoma (Hoon et al, 1991), breast and colon
carcinoma (Toi et al, 1992), and non-small cell lung carcinoma cell
lines (Topp et al, 1993a, b). On the other hand, IL-4 can modestly
stimulate the growth of human squamous cell carcinoma of head
and neck cell lines (Myers et al, 1996). The reason for contrasting
effect of IL-4 is not known. Since, medulloblastoma cell lines did
not respond to IL-4, it is reasonable to conclude that IL-4 is not
a paracrine growth factor for these cells. To determine the func-
tional activity of IL-4R on tumour cells, we and others have
shown that IL-4 can cause phosphorylation of JAK1, JAK2 and
STAT6 proteins in human colon carcinoma and ovarian carcinoma
cell lines even though IL-4 does not mediate autocrine or paracrine
growth of these tumour cell lines (Murata et al, 1995, 1997b).
These studies suggest that IL-4 induced signal transduction does
not seem to mediate growth of tumour cells. Signal transduction
may modulate growth inhibition or other unknown biological
effects on these cells, which are yet to be discovered. Further
studies are required to determine the signiﬁcance of IL-4R expres-
sion on medulloblastoma cell lines.
In conclusion, we report that, like GBM, medulloblastoma cell
lines also express IL-4R, which appears to be an efﬁcient target
for cpIL4-PE. Additional primary medulloblastoma tumour
samples need to be tested for their sensitivity to cpIL4-PE. In addi-
tion, the efﬁcacy of cpIL4-PE should be tested in animal models of
human medulloblastoma tumours and perhaps in the clinic for the
treatment of young children who have failed standard treatment.
Alternatively, this agent could be useful in paediatric patients
who are most susceptible to the deleterious effects of standard
treatment of radiation to developing brain.
NOTE ADDED IN PROOF
We have recently reported (Joshi et al, 2001) that 15 of 18 glioblas-
toma mutliforme tumours express IL-4 receptors in situ.I n
contrast, IL-4R protein was not detected by immunohistochemistry
in 11 different normal brain tissues including sections from one
paediatric brain.
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